Kathmere Capital Management LLC Makes New $242,000 Investment in Pfizer Inc. (NYSE:PFE)

Kathmere Capital Management LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,564 shares of the biopharmaceutical company’s stock, valued at approximately $242,000.

Several other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Madison Investment Advisors LLC purchased a new position in Pfizer during the 4th quarter worth $5,360,000. one8zero8 LLC purchased a new position in Pfizer during the 4th quarter worth $1,656,000. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in Pfizer by 3.6% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 600,366 shares of the biopharmaceutical company’s stock worth $15,928,000 after acquiring an additional 20,991 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on PFE shares. Citigroup lifted their price objective on shares of Pfizer from $23.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Morgan Stanley boosted their price target on shares of Pfizer from $31.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 30th. Redburn Atlantic cut their price target on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group boosted their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, Leerink Partners cut their price target on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $28.55.

Pfizer Trading Down 0.5%

Shares of PFE opened at $25.65 on Monday. The business’s 50-day moving average price is $23.89 and its 200-day moving average price is $24.78. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a market cap of $145.83 billion, a PE ratio of 18.59, a P/E/G ratio of 0.93 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the business posted $0.82 earnings per share. The company’s revenue was down 7.8% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.71%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.